Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO Study: Paricalcitol in CKD Stage 3B/4 With Left Ventricular Hypertrophy
2007-001689-34Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) and left ventricular hypertrophy (LVH) comparing Paricalcitol with Placebo (2 arms). Primary endpoint: Change in Left Ventricular Mass Index (LVMI). Started Feb 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
chronic kidney disease (CKD)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on 2007-001689-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001689-34.